AZD-3759

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category UNKNOWN
UNII 67SX9H68W2

Structure

InChI Key MXDSJQHFFDGFDK-CYBMUJFWSA-N
Smiles COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C
InChI
InChI=1S/C22H23ClFN5O3/c1-13-11-28(2)7-8-29(13)22(30)32-19-9-14-17(10-18(19)31-3)25-12-26-21(14)27-16-6-4-5-15(23)20(16)24/h4-6,9-10,12-13H,7-8,11H2,1-3H3,(H,25,26,27)/t13-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C22H23ClFN5O3
Molecular Weight 459.91
AlogP 4.31
Hydrogen Bond Acceptor 7.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 4.0
Polar Surface Area 79.82
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 32.0

Bioactivity

Mechanism of Action Action Reference
Epidermal growth factor receptor erbB1 inhibitor INHIBITOR PubMed PubMed
Protein: Epidermal growth factor receptor erbB1
Description: Epidermal growth factor receptor
Organism : Homo sapiens
P00533 ENSG00000146648
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase EGFR family
- 0-102 - - -
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Eph family
- - - - 83
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Src family
- 622 - - 58
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase VEGFR family
- 156 - - 57
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Dopamine receptor
- 797 - - -
Assay Description Organism Bioactivity Reference
Inhibition of EGFR exon19 deletion mutant phosphorylation in human PC9 cells Homo sapiens 7.4 nM
Inhibition of EGFR L858R mutant phosphorylation in human H3255 cells Homo sapiens 7.2 nM
Inhibition of EGFR exon19 deletion mutant (unknown origin) by HTRF assay in presence of Km of ATP Homo sapiens 0.2 nM
Inhibition of EGFR (unknown origin) by HTRF assay in presence of 2 mM of ATP Homo sapiens 102.0 nM
Inhibition of EGFR exon19 deletion mutant (unknown origin) by HTRF assay in presence of 2mM of ATP Homo sapiens 2.4 nM
Inhibition of EGFR L858R mutant (unknown origin) by HTRF assay in presence of Km of ATP Homo sapiens 0.2 nM
Inhibition of EGFR L858R mutant (unknown origin) by HTRF assay in presence of 2 mM of ATP Homo sapiens 7.6 nM
Inhibition of EGFR (unknown origin) by HTRF assay in presence of Km of ATP Homo sapiens 0.3 nM
Inhibition of EGFR phosphorylation in human H838 cells Homo sapiens 64.5 nM
Antiproliferative against human PC9 cells expressing EGFR exon19 deletion mutant after 72 hrs by MTS assay Homo sapiens 7.7 nM
Antiproliferative against human H3255 cells expressing EGFR L858R mutant after 72 hrs by MTS assay Homo sapiens 7.0 nM
Inhibition of recombinant EpHB4 (unknown origin) at 1 uM after 40 mins by scintillation counting analysis in presence of [gamma33P]-ATP Homo sapiens 83.0 %
Inhibition of recombinant Flt (unknown origin) at 1 uM after 40 mins by scintillation counting analysis in presence of [gamma33P]-ATP Homo sapiens 57.0 %
Inhibition of recombinant Fyn (unknown origin) at 1 uM after 40 mins by scintillation counting analysis in presence of [gamma33P]-ATP Homo sapiens 58.0 %
Inhibition of recombinant KDR (unknown origin) at 1 uM after 40 mins by scintillation counting analysis in presence of [gamma33P]-ATP Homo sapiens 62.0 %
Inhibition of recombinant Lck (unknown origin) at 1 uM after 40 mins by scintillation counting analysis in presence of [gamma33P]-ATP Homo sapiens 61.0 %
Inhibition of recombinant Lyn (unknown origin) at 1 uM after 40 mins by scintillation counting analysis in presence of [gamma33P]-ATP Homo sapiens 74.0 %
Inhibition of recombinant Src (unknown origin) at 1 uM after 40 mins by scintillation counting analysis in presence of [gamma33P]-ATP Homo sapiens 69.0 %
Inhibition of recombinant Yes (unknown origin) at 1 uM after 40 mins by scintillation counting analysis in presence of [gamma33P]-ATP Homo sapiens 87.0 %
Inhibition of recombinant KDR (unknown origin) after 40 mins by scintillation counting analysis in presence of [gamma33P]-ATP Homo sapiens 156.0 nM
Inhibition of recombinant Src (unknown origin) after 40 mins by scintillation counting analysis in presence of [gamma33P]-ATP Homo sapiens 622.0 nM
Inhibition of recombinant D2 receptor (unknown origin) Homo sapiens 797.0 nM
Inhibition of CYP1A2 (unknown origin) Homo sapiens 50.0 nM
Inhibition of CYP2B6 (unknown origin) Homo sapiens 50.0 nM
Inhibition of CYP2C8 (unknown origin) Homo sapiens 50.0 nM
Inhibition of CYP2C9 (unknown origin) Homo sapiens 50.0 nM
Inhibition of CYP2C19 (unknown origin) Homo sapiens 50.0 nM
Inhibition of CYP2D6 (unknown origin) Homo sapiens 50.0 nM
Inhibition of CYP3A4 (unknown origin) Homo sapiens 50.0 nM
Inhibition of CYP3A5 (unknown origin) Homo sapiens 50.0 nM
Antitumor activity against human PC9 cells expressing EGFR exon19 deletion mutant xenografted in mouse assessed as tumor growth inhibition at 7.5 mg/kg, qd measured after 4 weeks Homo sapiens 78.0 %
Antiproliferative activity against human H3255 cells after 72 hrs by MTT assay Homo sapiens 90.0 nM
Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay Homo sapiens 30.0 nM
Antiproliferative activity against human PC9 cells after 72 hrs by MTT assay Homo sapiens 50.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens -4.1 %
Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate measured after 20 mins in presence of [gamma33P]ATP by filter-binding assay Homo sapiens 0.5 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 15.25 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.23 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.23 %

Cross References

Resources Reference
ChEMBL CHEMBL3623290
DrugBank DB14795
FDA SRS 67SX9H68W2
Guide to Pharmacology 10456
SureChEMBL SCHEMBL16010006
ZINC ZINC000221149242
CONTENTS